We used mRNA expression of the type I IFN-responsive genes Ly6E, MX1, IFI44L and IFITM1 to determine the pre-treatment type I IFN score in the PBMCs from the melanoma patients in our study. This evidence concerns the gene IFI44L and melanoma.